22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
Q: I am a New York employer. What are the key parts of the new amendments to the New York Human Righ...
Read More >
Long used to prevent former employees from gaining an unfair competitive advantage, covenants not to...
Read More >
“What did I do wrong?” and “Am I doing this correctly?” are frequent questions from clients rega...
Read More >
Much like everything else in the world, M&A transactions must adjust in order to account for the imp...
Read More >
The global presence of the People’s Republic of China (China or PRC) in the construction space is u...
Read More >
In Farro v. Schochet, the Second Department recently held that §1002 of the NY LLC Law restricted a ...
Read More >